TABLE OF CONTENTS
1 INTRODUCTION 85
1.1 OBJECTIVES OF THE STUDY 85
1.2 MARKET DEFINITION 85
1.3 OVERVIEW OF THE GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET 85
1.4 CURRENCY AND PRICING 87
1.5 LIMITATIONS 88
1.6 MARKETS COVERED 88
2 MARKET SEGMENTATION 92
2.1 MARKETS COVERED 92
2.2 GEOGRAPHICAL SCOPE 93
2.3 YEARS CONSIDERED FOR THE STUDY 94
2.4 DBMR TRIPOD DATA VALIDATION MODEL 95
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 98
2.6 MULTIVARIATE MODELLING 99
2.7 MARKET APPLICATION COVERAGE GRID 100
2.8 TEST TYPE LIFELINE CURVE 101
2.9 DBMR MARKET POSITION GRID 102
2.10 VENDOR SHARE ANALYSIS 103
2.11 SECONDARY SOURCES 104
2.12 ASSUMPTIONS 104
3 EXECUTIVE SUMMARY 105
4 PREMIUM INSIGHTS 108
4.1 PESTEL ANALYSIS 111
4.2 PORTER'S 5 FORCES 112
4.3 EPIDEMIOLOGY 113
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 114
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 114
5 INDUSTRY INSIGHTS 115
6 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 117
7 MARKET OVERVIEW 120
7.1 DRIVERS 122
7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 122
7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 124
7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 125
7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 125
7.2 RESTRAINTS 126
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 126
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 127
7.3 OPPORTUNITIES 127
7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 127
7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 128
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 128
7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 129
7.4 CHALLENGES 129
7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 129
7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 130
8 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131
8.1 OVERVIEW 132
8.2 IMAGING 136
8.2.1 COMPUTED TOMOGRAPHY 137
8.2.2 ULTRASOUND 137
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 137
8.2.4 ANGIOGRAPHY 137
8.2.5 X-RAY 137
8.2.6 OTHERS 137
8.3 BLOOD TEST 137
8.4 BIOPSY 138
8.4.1 FINE NEEDLE ASPIRATION 139
8.4.2 NEEDLE CORE BIOPSY 139
8.5 BIOMARKER TEST 139
8.5.1 AQUAPORIN 1 (AQP1) 141
8.5.2 PERILIPIN (PLIN2) 141
8.5.3 N-METHYLTRANSFERASE (NMNT) 141
8.5.4 L-PLASTIN (LCP-1) 141
8.5.5 NM23A 141
8.6 GENETIC TEST 141
8.7 OTHERS 142
9 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 144
9.1 OVERVIEW 145
9.2 STAGE I 148
9.3 STAGE II 148
9.4 STAGE III 149
9.5 STAGE IV 150
10 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 151
10.1 OVERVIEW 152
10.2 RENAL CELL CARCINOMA 156
10.2.1 IMAGING 157
10.2.2 BLOOD TEST 157
10.2.3 BIOPSY 157
10.2.4 BIOMARKER TEST 157
10.2.5 GENETIC TEST 157
10.2.6 OTHERS 157
10.3 CLEAR CELL RENAL CELL CARCINOMA 157
10.3.1 IMAGING 159
10.3.2 BLOOD TEST 159
10.3.3 BIOPSY 159
10.3.4 BIOMARKER TEST 159
10.3.5 GENETIC TEST 159
10.3.6 OTHERS 159
10.4 NON CLEAR CELL RENAL CELL CARCINOMA 159
10.4.1 PAPILLARY RENAL CELL CARCINOMA 160
10.4.1.1 IMAGING 161
10.4.1.2 BLOOD TEST 161
10.4.1.3 BIOPSY 161
10.4.1.4 BIOMARKER TEST 161
10.4.1.5 GENETIC TEST 161
10.4.1.6 OTHERS 161
10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 161
10.4.2.1 IMAGING 162
10.4.2.2 BLOOD TEST 162
10.4.2.3 BIOPSY 162
10.4.2.4 BIOMARKER TEST 162
10.4.2.5 GENETIC TEST 162
10.4.2.6 OTHERS 162
11 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 163
11.1 OVERVIEW 164
11.2 INSTRUMENT BASED PRODUCTS 168
11.2.1 IMAGING 169
11.2.2 BIOPSY 169
11.3 PLATFORM BASED PRODUCTS 169
11.3.1 NEXT GENERATION SEQUENCING 171
11.3.2 MICROARRAYS 171
11.3.3 PCR 172
11.3.4 OTHERS 172
11.4 KITS AND REAGENTS 172
11.4.1 RENAL CANCER PANELS 174
11.4.2 RENAL CANCER ANTIBODIES 174
11.5 OTHER CONSUMABLES 174
12 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 175
12.1 OVERVIEW 176
12.2 FLUORESCENT IN SITU HYBRIDIZATION 179
12.3 NEXT GENERATION SEQUENCING 179
12.4 FLUORIMMUNOASSAY 180
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 181
12.6 IMMUNOHISTOCHEMICAL 182
12.7 OTHERS 182
13 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 184
13.1 OVERVIEW 185
13.2 SCREENING 188
13.2.1 INSTRUMENT BASED PRODUCTS 189
13.2.2 PLATFORM BASED PRODUCTS 189
13.2.3 KITS AND REAGENTS 189
13.2.4 OTHER CONSUMABLES 189
13.3 DIAGNOSTIC AND PREDICTIVE 189
13.3.1 INSTRUMENT BASED PRODUCTS 190
13.3.2 PLATFORM BASED PRODUCTS 190
13.3.3 KITS AND REAGENTS 190
13.3.4 OTHER CONSUMABLES 190
13.4 PROGNOSTIC 191
13.4.1 INSTRUMENT BASED PRODUCTS 192
13.4.2 PLATFORM BASED PRODUCTS 192
13.4.3 KITS AND REAGENTS 192
13.4.4 OTHER CONSUMABLES 192
13.5 RESEARCH 192
13.5.1 INSTRUMENT BASED PRODUCTS 193
13.5.2 PLATFORM BASED PRODUCTS 193
13.5.3 KITS AND REAGENTS 193
13.5.4 OTHER CONSUMABLES 194
14 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 195
14.1 OVERVIEW 196
14.2 HOSPITALS 199
14.3 DIAGNOSTIC CENTERS 199
14.4 CANCER RESEARCH CENTERS 200
14.5 ACADEMIC INSTITUTES 201
14.6 AMBULATORY SURGICAL CENTERS 201
14.7 OTHERS 202
15 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 203
15.1 OVERVIEW 204
15.2 DIRECT TENDER 207
15.3 RETAIL SALES 207
15.4 OTHERS 208
16 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 209
16.1 OVERVIEW 210
16.2 NORTH AMERICA 216
16.2.1 U.S. 230
16.2.2 CANADA 239
16.2.3 MEXICO 248
16.3 ASIA-PACIFIC 257
16.3.1 CHINA 270
16.3.2 JAPAN 277
16.3.3 INDIA 284
16.3.4 SOUTH KOREA 291
16.3.5 AUSTRALIA 298
16.3.6 TAIWAN 305
16.3.7 NEW ZEALAND 313
16.3.8 INDONESIA 320
16.3.9 THAILAND 327
16.3.10 PHILIPPINES 334
16.3.11 MALAYSIA 341
16.3.12 VIETNAM 348
16.3.13 SINGAPORE 355
16.3.14 REST OF ASIA PACIFIC 362
16.4 EUROPE 363
16.4.1 GERMANY 379
16.4.2 FRANCE 388
16.4.3 UNITED KINGDOM 397
16.4.4 ITALY 406
16.4.5 SPAIN 415
16.4.6 RUSSIA 424
16.4.7 NETHERLANDS 433
16.4.8 POLAND 442
16.4.9 SWITZERLAND 451
16.4.10 BELGIUM 460
16.4.11 SWEDEN 469
16.4.12 NORWAY 478
16.4.13 DENMARK 487
16.4.14 FINLAND 496
16.4.15 TURKEY 505
16.4.16 REST OF EUROPE 514
16.5 SOUTH AMERICA 515
16.5.1 BRAZIL 527
16.5.2 ARGENTINA 534
16.5.3 REST OF SOUTH AMERICA 542
16.6 MIDDLE EAST AND AFRICA 543
16.6.1 SOUTH AFRICA 556
16.6.2 SAUDI ARABIA 563
16.6.3 BAHRAIN 571
16.6.4 U.A.E. 578
16.6.5 EGYPT 586
16.6.6 ISRAEL 594
16.6.7 KUWAIT 602
16.6.8 OMAN 610
16.6.9 QATAR 618
16.6.10 REST OF MIDDLE EAST AND AFRICA 626
17 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 627
17.1 COMPANY SHARE ANALYSIS: GLOBAL 627
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 628
17.3 COMPANY SHARE ANALYSIS: EUROPE 629
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 630
18 SWOT ANALYSIS 631
19 COMPANY PROFILE 632
19.1 CANON MEDICAL SYSTEMS CORPORATION 632
19.1.1 COMPANY SNAPSHOT 632
19.1.2 REVENUE ANALYSIS 632
19.1.3 COMPANY PROFILE 633
19.1.4 PRODUCT PORTFOLIO 633
19.1.5 RECENT DEVELOPMENT 633
19.2 KONINKLIJKE PHILIPS N.V. 634
19.2.1 COMPANY SNAPSHOT 634
19.2.2 REVENUE ANALYSIS 634
19.2.3 COMPANY PROFILE 635
19.2.4 PRODUCT PORTFOLIO 635
19.2.5 RECENT DEVELOPMENTS 636
19.3 GENERAL ELECTRIC COMPANY 637
19.3.1 COMPANY SNAPSHOT 637
19.3.2 REVENUE ANALYSIS 637
19.3.3 COMPANY PROFILE 638
19.3.4 PRODUCT PORTFOLIO 638
19.3.5 RECENT DEVELOPMENTS 639
19.4 SIEMENS HEALTHCARE GMBH 640
19.4.1 COMPANY SNAPSHOT 640
19.4.2 REVENUE ANALYSIS 640
19.4.3 COMPANY PROFILE 641
19.4.4 PRODUCT PORTFOLIO 641
19.4.5 RECENT DEVELOPMENT 642
19.5 GRAIL 643
19.5.1 COMPANY SNAPSHOT 643
19.5.2 PRODUCT PORTFOLIO 643
19.5.3 RECENT DEVELOPMENTS 643
19.6 AMBRY GENETICS 645
19.6.1 COMPANY SNAPSHOT 645
19.6.2 PRODUCT PORTFOLIO 645
19.6.3 RECENT DEVELOPMENT 645

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.